Treatment of Cushing's Disease in Pregnant Women or Women Desiring Pregnancy
Clinical Scenario
This protocol addresses Cushing's disease specifically in pregnant women and in women who are planning to become pregnant — a population where clinical decisions must account for both maternal and reproductive considerations.
First-Line Approach
First-line definitive management centers on a surgical approach to the pituitary gland. The full evidence-based regimen — including decision criteria, sequencing, and population-specific considerations — is available in the structured protocol.
Treatment Goal
The primary clinical objective is remission, defined as postoperative serum cortisol <55 nmol/L (<2 μg/dL).
References
DOI: 10.1016/S2213-8587(21)00235-7
- In pregnant women or those desiring pregnancy, consider cabergoline or metyrapone, although no CD medications are approved for use in pregnancy.
- Many expert centers recommend BLA earlier in the course of the disease for females with CD desiring pregnancy.
- Transsphenoidal surgery (TSS) is recommended as first-line therapy for patients with CD.
- Remission, typically defined as postoperative serum cortisol <55 nmol/L (<2 μg/dL), is seen in approximately 80% of patients with microadenomas and 60% with macroadenomas if the procedure is performed by an experienced surgeon.